Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

2

Revenue 2017

Revlimid

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Revlimid was produced by Celgene.

NICE backs Celgene's Revlimid in rare blood cancer

NICE backs Celgene's Revlimid in rare blood cancer Patient access scheme sways the HTA body. NICE has recommended Celgene's Revlimid (lenalidomide) be used by the NHS in England and Wales for the rare blood cancer myelodysplastic syndromes (MDS). ... Revlimid was recommended for people with low- or

NICE backs Celgene’s Revlimid in bone marrow disorder

NICE backs Celgene’s Revlimid in bone marrow disorder Final draft guidance published by NICE says that Revlimid (lenalidomide) should be available on the NHS in England and Wales to treat myelodysplastic syndromes. ... However, Celgene has since agreed to provide Revlimid at a discount to the NHS in this

Amgen hit as Kyprolis fails myeloma study

Amgen hit as Kyprolis fails myeloma study Celgene's Revlimid (lenalidomide) and dexamethasone.

Amgen closes on second-line use for Kyprolis

Amgen closes on second-line use for Kyprolis The ASPIRE study compared Kyprolis (carfilzomib) to placebo on top of Celgene's Revlimid (lenalidomide) and dexamethasone therapy in patients with relapsed multiple myeloma, and found Amgen's drug significantly improved ... Drugs such as Velcade and

NICE set to block post-Velcade use of Revlimid

NICE set to block post-Velcade use of Revlimid New draft guidance from NICE does not recommend the use of Celgene's Revlimid (lenalidomide) to treat multiple myeloma in patients who have relapsed after taking Janssen's Velcade.  . ... Revlimid would also not be recommended in those for whom

[ Previous 5 results ] 11 12 13 14 15 16 17 18 19 20 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics